P84 High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial

1998 ◽  
Vol 34 ◽  
pp. S36 ◽  
Author(s):  
E. Galligioni ◽  
G. Cetto ◽  
O. Nascimben ◽  
A. Buonadonna ◽  
D. Crivellari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Randomized Trial ◽  
Cancer Patients ◽  
Prospective Randomized Trial ◽  
High Dose ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.

1997 ◽  
Vol 15 (10) ◽  
pp. 3178-3184 ◽  
Author(s):  
R García-Carbonero ◽  
M Hidalgo ◽  
L Paz-Ares ◽  
J Calzas ◽  
H Gómez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
High Dose ◽  
Breast Cancer Patients ◽  
Short Term ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

PURPOSE To evaluate the impact of the selection criteria that are used in current high-dose consolidation chemotherapy (HDCT) trials on the outcome of high-risk breast cancer patients treated with conventional adjuvant chemotherapy. PATIENTS AND METHODS From 1975 to 1995, 265 breast cancer patients at our institution showed involvement of ten or more positive axillary lymph nodes. Of these, 171 received standard adjuvant combination chemotherapy, but not HDCT consolidation, and were the subjects of our study. One hundred twenty-eight patients met the standard selection criteria for HDCT with hematological support (< 60 years, no significant concomitant disease, and no progression during adjuvant treatment), whereas 43 did not. Clinical outcome was analyzed by using disease-free survival (DFS) and overall survival (OS) as endpoints. To provide an assessment of the short-term efficacy of HDCT, we also evaluated the outcome in a cohort of 39 patients from the last 4 years who met the criteria for, and were actually treated with, HDCT after adjuvant chemotherapy. RESULTS With a median follow-up of 4.4 years (range, 0.7 to 17.2 years), 112 of the 171 patients have had a relapse, and 87 have died. The estimated 5-year DFS was 32.3%, and OS was 49.4%. DFS was significantly higher for patients who met the HDCT criteria (36.6% at 5 years) than for those who did not (15.8% at 5 years; P < .05). OS was also significantly more favorable in patients meeting HDCT criteria (55.4% at 5 years) than in patients not meeting HDCT criteria (22.7% at 5 years; P < .01). We performed a multivariate analysis to adjust for other potential prognostic factors and found that meeting the HDCT criteria and having undergone locoregional radiotherapy were the only significant independent predictors for DFS and OS. Finally, we compared the outcome of the 128 patients who met the HDCT criteria and were treated with conventional adjuvant chemotherapy only with that of the 39 patients who met the criteria and who actually underwent HDCT, and we did not observe significant differences in the DFS or OS between these groups. CONCLUSIONS Meeting HDCT inclusion criteria is an independent indicator of favorable prognosis in high-risk breast cancer patients. The selection of patients by these criteria may explain, at least in part, the promising short-term results of nonrandomized adjuvant HDCT trials in high-risk breast cancer.

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies

2017 ◽  
Vol 71 ◽  
pp. 34-42 ◽  
Author(s):  
Matteo Lambertini ◽  
Marcello Ceppi ◽  
Francesco Cognetti ◽  
Giovanna Cavazzini ◽  
Michele De Laurentiis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Pooled Analysis ◽  
Phase Iii ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Dose Dense ◽  
Phase Iii Studies

Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era

2009 ◽  
Vol 20 (6) ◽  
pp. 503-507 ◽  
Author(s):  
Alessandro Marco Minisini ◽  
Jessica Menis ◽  
Francesca Valent ◽  
Claudia Andreetta ◽  
Barbara Alessi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document